Evaluation of a CD5-specific immunotoxin for treatment of acute graft- versus-host disease after allogeneic marrow transplantation

Blood

Volumn 88, Issue 3, 1996, Pages 824-830

  Martin, Paul J ^a   Nelson, Betty J ^b   Appelbaum, Frederick R ^b   Anasetti, Claudio ^b   Deeg, H Joachim ^b   Hansen, John A ^b   McDonald, George B ^b   Nash, Richard A ^b   Sullivan, Keith M ^b   Witherspoon, Robert P ^b   Scannon, Patrick J ^b   Friedmann, Nadav ^b   Storb, Rainer ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; PREDNISONE; XOMAZYME;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; EDEMA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERBILIRUBINEMIA; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VOMITING;

EID: 8044219688     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.3.824.bloodjournal883824     Document Type: Article

References (35)

1. Sullivan KM: Graft-versus-host disease, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Boston, MA, Blackwell Scientific, 1994, p 339
2. Ferrara JLM, Deeg HJ: Graft-versus-host disease. N Engl J Med 324:667, 1991
3. Prentice HG, Bateman SM, Bradstock KF, Hoffbrand AV: High dose methylprednisolone therapy in established acute graft-versus-host disease. Blut 41:175, 1980
4. Doney KC, Weiden PL, Storb R, Thomas ED: Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: A randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 11:1, 1981
5. Kendra J, Barrett AJ, Lucas C, Joshi R, Joss V, Desai M, Halil O, Rogers TR, Hobbs JR, Hugh-Jones K: Response of graft-versus-host disease to high doses of methylprednisolone. Clin Lab Haematol 3:19, 1981
6. Bacigalupo A, van Lint MT, Frassoni F, Podesta' M, Veneziano G, Avanzi G, Vitale V, Marmont AM: High dose bolus methylprednisolone for the treatment of acute graft-versus-host disease. Blut 46:125, 1983
7. Kanojia MD, Anagnostou AA, Zander AR, Vellekoop L, Spitzer G, Verma DS, Jagannath S, Dicke KA: High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation 37:246, 1984
8. Kennedy MS, Deeg HJ, Storb R, Doney K, Sullivan KM, Witherspoon RP, Appelbaum FR, Stewart P, Sanders J, Buckner CD, Martin P, Weiden P, Thomas ED: Treatment of acute graft-versus-host disease after allogeneic marrow transplantation: A randomized study comparing corticosteroids and cyclosporine. Am J Med 78:978, 1985
9. Deeg HJ, Loughran TP, Storb R, Kennedy MS, Sullivan KM, Doney K, Appelbaum FR, Thomas ED: Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 40:162, 1985
10. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, Beatty PG, Doney K, McDonald GB, Sanders JE, Sullivan KM, Storb R, Thomas ED, Witherspoon RP, Lomen P, Hannigan J, Hansen JA: A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 76:1464, 1990
11. Hings IM, Severson R, Filipovich AH, Blazar BR, Kersey JH, Ramsay NK, McGlave PB, Weisdorf DJ: Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 58:437, 1994
12. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB, Hansen JA: A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment. Blood 77:1821, 1991
13. Kernan NA, Knowles RW, Burns MJ, Broxmeyer HE, Lee HM, Kawahata RT, Scannon PJ, Dupont B: Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin. J Immunol 133:137, 1984
14. Kernan NA, Byers V, Scannon PJ, Mischak RP, Brochstein J, Flomenberg N, Dupont B, O'Reilly RJ: Treatment of steroid-resistant acute graft-versus-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin. JAMA 259:3154, 1988
15. Byers VS, Henslee PJ, Kernan NA, Blazar BR, Gingrich R, Phillips GL, LeMaistre CF, Gilliland G, Antin JH, Martin P, Tutscha PJ, Trown P, Ackerman SK, O'Reilly RJ, Scannon PJ: Use of an anti-pan T-lymphocyte ricin A chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood 75:1426, 1990
16. Efron B: Forcing a sequential trial to be balanced. Biometrika 58:403, 1971
17. Efron B: Randomizing and balancing a complicated sequential experiment, in Miller RG Jr, Efron B, Brown BW Jr, Moses LE (eds): Biostatistics Casebook. New York, NY, Wiley, 1980, p 19
18. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 18:295, 1974
19. Yasmineh WG, Killeen AA, Filipovich AH: Conjugated hyperbilirubinemia and renal function in bone marrow transplant recipients. Arch Pathol Lab Med 112:245, 1988
20. LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Drajesk J, Fishwild D, Scannon P, Byers V: Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 78:1173, 1991
21. Koch GG, Carr GJ, Amara IA, Stokes ME, Uryniak TJ, in Berry DA (ed): Statistical Methodology in the Pharmaceutical Sciences. New York, NY, Marcel Dekker, 1990, p 423
22. Nestel FP, Price KS, Seemayer TA, Lapp WS: Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175:405, 1992
23. Akerblom IE, Slater EP, Beato M, Baxter JD, Mellon PL: Negative regulation by glucocorticoids through interference with a cAMP responsive enhancer. Science 241:350, 1988
24. Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science 270:286, 1995
25. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS: Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270:283, 1995
26. Gerrard TL, Cupps TR, Jurgensen CH, Fauci AS: Hydrocortisone-mediated inhibition of monocyte antigen presentation: Dissociation of inhibitory effect and expression of DR antigens. Cell Immunol 85:330, 1984
27. Mokoena T, Gordon S: Human macrophage activation. Modulation of mannosyl, fucosyl receptor activity in vitro by lymphokines, gamma and alpha interferons, and dexamethasone. J Clin Invest 75:624, 1985
28. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A: Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. Science 232:977, 1986
29. Gillis S, Crabtree GR, Smith KA: Glucocorticoid-induced inhibition of T cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J Immunol 123:1632, 1979
30. Horst HJ, Flad HD: Corticosteroid-interleukin 2 interactions: Inhibition of binding of interleukin 2 to interleukin 2 receptors. Clin Exp Immunol 68:156, 1987
31. Galili N, Galili U, Klein E, Rosenthal L, Nordenskjold B: Human T lymphocytes become glucocorticoid-sensitive upon immune activation. Cell Immunol 50:440, 1980
32. Fishwild DM, Staskawicz MO, Wu H-M, Carroll SF: Cytotoxicity against human peripheral blood mononuclear cells and T cell lines mediated by anti-T cell immunotoxins in the absence of added potentiator. Clin Exp Immunol 86:506, 1991
33. Strand V, Lipsky PE, Cannon GW, Calabrese LH, Wiesenhutter C, Cohen SB, Olsen NJ, Lee ML, Lorenz TJ, Nelson B, and the CD5 Plus Rheumatoid Arthritis Investigators Group: Effects of administration of an anti-CD5 Plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. Arth Rheum 36:620, 1993
34. Skyler JS, Lorenz TJ, Schwartz S, Eisenbarth GS, Einhorn D, Palmer JP, Marks JB, Greenbaum C, Sana EA, Byers V, and the CD5 Diabetes Project Team: J Diab Comp 7:224, 1993
35. Fishwild DM, Strand V: Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis: Effect on peripheral blood mononuclear cells and in vitro immune function. J Rheumatol 21:596, 1994